Kodiak Sciences Inc. (KOD) Reports Complete Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Kodiak Sciences Inc. (KOD) Prices 5.19M Share Common Offering at $108/Sh
November 18, 2020 5:49 AM ESTKodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an underwritten public offering of 5,193,237 shares of its common stock at a price to the public of $108.00... More
UPDATE: Morgan Stanley Downgrades Kodiak Sciences Inc. (KOD) to Equalweight
November 16, 2020 3:21 AM EST(Updated - November 16, 2020 5:47 AM EST)
(updating comment)
Morgan Stanley analyst Matthew Harrison downgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Overweight to Equalweight with a price target of $125.00.
The analyst comments "We remain bullish on KSI-301's durability profile,... More
UPDATE: Goldman Sachs Downgrades Kodiak Sciences Inc. (KOD) to Neutral
November 13, 2020 4:41 AM EST(Updated - November 13, 2020 6:01 AM EST)
(updating comment)
Goldman Sachs analyst Graig Suvannavejh downgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Buy to Neutral with a price target of $105.00.
The analyst comments "We raise our 12 month price target on Kodiak Sciences (KOD) to... More
Kodiak Sciences Inc. (KOD) PT Raised to $145 at BMO Capital
November 12, 2020 10:45 AM ESTBMO Capital analyst Matthew Luchini raised the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $145.00 while maintaining an Outperform rating.
The analyst commented, "We are raising our target price to $145 on higher probability of success (67% vs. 45%) and peak US wAMD share (20% vs. 17%). Our... More
